

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ANALYTICA LIMITED
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Michael Monsour
Date of last notice	13th June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	7th June 2019
o. of securities held prior to change	<u>Ordinary Shares</u> Dr Michael Monsour • 3,587,713 Ordinary Shares MPAMM Pty Ltd • 199,750,620 Ordinary Shares MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 156,379,178 Ordinary Shares Halonna Pty Ltd < Monsour Family A/C • 413,661,334 ordinary shares <u>Unlisted options</u> MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 13,000,000 unlisted options expiring 29 October 2018 • 20,000,000 unlisted options expiring 22 December 2021

Appendix 3Y

Change of Director's Interest Notice

Class	Ordinary shares
Number acquired/disposed	<p><u>Ordinary Shares</u> Dr Michael Monsour • 597,286 Ordinary Shares MPAMM Pty Ltd • 33,291,770 Ordinary Shares Halonna Pty Ltd < Monsour Family A/C 68,743,556 ordinary shares</p> <p>Unlisted options -MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 13,000,000 unlisted options expired 29 October 2018</p>
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$514,163
No. of securities held after change	<p><u>Ordinary Shares</u> Dr Michael Monsour • 4,180,999 Ordinary Shares MPAMM Pty Ltd • 233,042,390 Ordinary Shares MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 156,379,178 Ordinary Shares Halonna Pty Ltd < Monsour Family A/C • 482,604,890 ordinary shares</p> <p><u>Unlisted options</u> MP Monsour Medical Practice Pty Ltd <Superannuation Account> • 20,000,000 unlisted options expiring 22 December 2021</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of entitlement of share under share offer to all shareholders

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	-
Interest acquired	-
Interest disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
Interest after change	-

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ANALYTICA LIMITED
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Mangelsdorf
Date of last notice	15th June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Tambien Pty Ltd and Edmonmont (Mr Mangelsdorf is a director, shareholder, trustee)
Date of change	7th June 2019
No. of securities held prior to change	Ordinary Shares Ross James Mangelsdorf • 298,939 Ordinary Shares Ross Mangelsdorf & Jennifer Margaret Mangelsdorf • 298,939 Ordinary Shares Tambien Pty Ltd • 58,015,811 Ordinary Shares Edmonmont • 33,870,510 ordinary shares Unlisted options • 10,000,000 unlisted options expiring date 29 October 2018 • 10,000,000 unlisted options. Expiry date 22 December 2021 • 10,000,000 unlisted options expiring 30 November 2022 with an exercise price of \$0.013 (Tambien Pty Ltd)

Appendix 3Y

Change of Director's Interest Notice

Class	Ordinary Shares
Number acquired/disposed	<u>Ordinary Shares acquired</u> Ross James Mangelsdorf <ul style="list-style-type: none"> • 49,824 Ordinary Shares Ross Mangelsdorf & Jennifer Margaret Mangelsdorf <ul style="list-style-type: none"> • 49,824 Ordinary Shares Tambien Pty Ltd <ul style="list-style-type: none"> • 9,669,305 Ordinary Shares Edmonmont <ul style="list-style-type: none"> • 5,645,087 Ordinary shares Unlisted options 10,000,000 unlisted options expired 29 October 2018
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$77,070
No. of securities held after change	<u>Ordinary Shares acquired</u> Ross James Mangelsdorf <ul style="list-style-type: none"> • 348,763 Ordinary Shares Ross Mangelsdorf & Jennifer Margaret Mangelsdorf <ul style="list-style-type: none"> • 348,763 Ordinary Shares Tambien Pty Ltd <ul style="list-style-type: none"> • 67,685,116 Ordinary Shares Edmonmont <ul style="list-style-type: none"> • 40,627,000 Ordinary shares <u>Unlisted options</u> <ul style="list-style-type: none"> • 10,000,000 unlisted options. Expiry date 22 December 2021 • 10,000,000 unlisted options expiring 30 November 2022 with an exercise price of \$0.013 (Tambien Pty Ltd)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of entitlement under share offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
---------------------------	---

Appendix 3Y
Change of Director's Interest Notice

Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	-
Interest acquired	-
Interest disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
Interest after change	-

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a